This review highlights the exponential but heterogeneous adoption of TAVI across Western European nations since its commercialization in 2007.
Heterogeneous TAVI adoption across Western Europe may indicate access disparities; leaves open drivers of variation and need for implementation research.
Transcatheter aortic valve implantation (TAVI) is a novel therapeutic option for patients with severe symptomatic aortic stenosis (AS) at excessive or high surgical risk for conventional surgical aortic valve replacement. First commercialised in Europe in 2007, TAVI growth has been exponential among some Western European nations, though recent evidence suggests heterogeneous adoption of this new and expensive therapy. Herein, we review the evidence describing the utilisation of TAVI in Western Europe.
No takes yet. Share an insight, caveat, or question.
Mylotte et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: